News & Updates

Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.

Administration of oral silymarin leads to a substantial decrease in hepatotoxicity severity after 1 month of treatment in nonmetastatic breast cancer patients on doxorubicin/cyclophosphamide-paclitaxel (AC-T) regimen, reports a study.

In patients with relapsed/refractory multiple myeloma (R/R MM), a combination of melflufen and dexamethasone proved better than an approved doublet standard-of-care (SoC) comprising pomalidomide-dexamethasone in terms of progression-free survival (PFS), the phase III OCEAN trial has shown. However, the overall survival (OS) outcome with the melflufen-containing regimen appeared to digress from the PFS result, potentially casting doubt on its benefit for this condition.

Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.

In women with breast cancer, oncoplastic surgery improves quality of life and is associated with high patient satisfaction, reports a new study.

Taking a statin after breast cancer surgery appears to reduce the risk of disease recurrence in Asians, especially among those with invasive cancers, as shown in a study from Singapore.